These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 25741635)

  • 1. Acute vision loss after ocriplasmin use.
    Reiss B; Smithen L; Mansour S
    Retin Cases Brief Rep; 2015; 9(2):168-9. PubMed ID: 25741635
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vision loss after intravitreal ocriplasmin: correlation of spectral-domain optical coherence tomography and electroretinography.
    Tibbetts MD; Reichel E; Witkin AJ
    JAMA Ophthalmol; 2014 Apr; 132(4):487-90. PubMed ID: 24577286
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Severe acute vision loss, dyschromatopsia, and changes in the ellipsoid zone on sd-oct associated with intravitreal ocriplasmin injection.
    Quezada Ruiz C; Pieramici DJ; Nasir M; Rabena M; Avery RL
    Retin Cases Brief Rep; 2015; 9(2):145-8. PubMed ID: 25462129
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute loss of vision after an intravitreal injection ocriplasmin: a functional evolutionary study for 1-year follow-up.
    Gómez-Ulla F; Bande MF; Abraldes M
    Doc Ophthalmol; 2015 Dec; 131(3):231-5. PubMed ID: 26542118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transient vision loss after ocriplasmin injection.
    Reiss B; Smithen L; Mansour S
    Retina; 2015 Jun; 35(6):1107-10. PubMed ID: 25901839
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Flat Electroretinography and Acute Visual Loss After Ocriplasmin Injection for Vitreomacular Adhesion Complicating Macular Schisis.
    Hale BP; Au AK; Falk NS; Bhatnagar P; Beer PM
    Ophthalmic Surg Lasers Imaging Retina; 2015 Sep; 46(8):888-92. PubMed ID: 26431307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. WIDESPREAD MACULAR NEUROSENSORY DETACHMENT AFTER OCRIPLASMIN INTRAVITREAL INJECTION.
    Neffendorf JE; Lim LT; Gout II; El-Amir A
    Retin Cases Brief Rep; 2016; 10(4):354-6. PubMed ID: 26674272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Unclear retinopathy after intravitreal injection of ocriplasmin].
    Abraham S; Wand K; Stumpfe S; Feucht N; Lohmann CP; Maier M
    Ophthalmologe; 2016 Feb; 113(2):156-9. PubMed ID: 26205745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PERSISTENT RETINAL CHANGES AFTER INTRAVITREAL OCRIPLASMIN.
    Margo JA; Schocket LS; Klima K; Johnson MA
    Retin Cases Brief Rep; 2016; 10(1):48-51. PubMed ID: 26682796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reversible vision loss and outer retinal abnormalities after intravitreal ocriplasmin injection.
    Thanos A; Hernandez-Siman J; Marra KV; Arroyo JG
    Retin Cases Brief Rep; 2014; 8(4):330-2. PubMed ID: 25372540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute panretinal structural and functional abnormalities after intravitreous ocriplasmin injection.
    Fahim AT; Khan NW; Johnson MW
    JAMA Ophthalmol; 2014 Apr; 132(4):484-6. PubMed ID: 24577241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complications of intravitreal ocriplasmin for vitreomacular traction and macular hole: a prospective spectral-domain optical coherence tomography study.
    Chatziralli IP; Theodossiadis GP; Parikakis E; Datseris I; Theodossiadis P
    Cutan Ocul Toxicol; 2016 Dec; 35(4):263-9. PubMed ID: 26555379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Longitudinal ellipsoid zone and subretinal fluid mapping following ocriplasmin injection in the prospective observational ORBIT trial.
    Lavine JA; Srivastava SK; Dukles N; Reese JL; Ehlers JP
    Br J Ophthalmol; 2020 Mar; 104(3):410-415. PubMed ID: 31248879
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anatomical and visual outcomes following ocriplasmin treatment for symptomatic vitreomacular traction syndrome.
    Singh RP; Li A; Bedi R; Srivastava S; Sears JE; Ehlers JP; Schachat AP; Kaiser PK
    Br J Ophthalmol; 2014 Mar; 98(3):356-60. PubMed ID: 24357495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vitrectomy After ocriplasmin for VitreOmacular adhesion Or Macular hole (VAVOOM) study.
    Greven MA; Garg S; Chiu B; Shah SP; Wolfe J; Fine HF; Roth DB; Robinson J; Mong J; Hsu J; Regillo C; Ho A; Haller JA
    Br J Ophthalmol; 2016 Sep; 100(9):1211-5. PubMed ID: 26659344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. COMPARISON OF RESOLUTION OF VITREOMACULAR TRACTION AFTER OCRIPLASMIN TREATMENT OR VITRECTOMY.
    Scholz P; Sitnilska V; Hess J; Becker M; Michels S; Fauser S
    Retina; 2019 Jan; 39(1):180-185. PubMed ID: 29135889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transient Subfoveal Fluid and Visual Loss after Ocriplasmin.
    Tschuppert S; Gerding H
    Klin Monbl Augenheilkd; 2016 Apr; 233(4):453-5. PubMed ID: 27116507
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Post-Market Experience With Ocriplasmin Including Chronic Electrophysiologic Changes.
    Small KW; Shaya FS; La Fontaine M
    Ophthalmic Surg Lasers Imaging Retina; 2015 Oct; 46(9):956-62. PubMed ID: 26469236
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LONG-TERM OUTCOMES IN PATIENTS WITH VITREOMACULAR TRACTION TREATED WITH A SINGLE INTRAVITREAL INJECTION OF OCRIPLASMIN.
    Tyler L; Singer M; Bell D
    Retin Cases Brief Rep; 2017 Winter; 11(1):34-37. PubMed ID: 26849382
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Understanding the adverse effects of ocriplasmin.
    Beebe DC
    JAMA Ophthalmol; 2015 Feb; 133(2):229. PubMed ID: 25376025
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.